Journal
CANCER CELL
Volume 14, Issue 4, Pages 335-343Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2008.08.014
Keywords
-
Categories
Funding
- NIH [NCI K22 CA1 13557, U54 CA119367, P30 CA82103, N01 HV28183, P01 CA34233, P01 CA108631]
- Leukemia & Lymphoma Society [LLS 7017-06, 2157-08, 7019-04]
- V Foundation for Cancer Research
- Campini Foundation
Ask authors/readers for more resources
Progress in understanding the molecular pathogenesis of human myeloproliferative disorders (MPDs) has led to guidelines incorporating genetic assays with histopathology during diagnosis. Advances in flow cytometry have made it possible to simultaneously measure cell type and signaling abnormalities arising as a consequence of genetic pathologies. Using flow cytometry, we observed a specific evoked STAT5 signaling signature in a subset of samples from patients suspected of having juvenile myelomonocytic leukemia (JMML), an aggressive MPD with a challenging clinical presentation during active disease. This signature was a specific feature involving JAK-STAT signaling, suggesting a critical role of this pathway in the biological mechanism of this disorder and indicating potential targets for future therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available